

**AMFR Antibody (C-term) Blocking Peptide**  
Synthetic peptide  
Catalog # BP2162a**Specification**

---

**AMFR Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [O9UKV5](#)  
Other Accession [P26442](#)**AMFR Antibody (C-term) Blocking Peptide - Additional Information**

Gene ID 267

**Other Names**

E3 ubiquitin-protein ligase AMFR, 632-, Autocrine motility factor receptor, AMF receptor, RING finger protein 45, gp78, AMFR, RNF45

**Target/Specificity**The synthetic peptide sequence used to generate the antibody [AP2162a](#) was selected from the C-term region of human AMFR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**AMFR Antibody (C-term) Blocking Peptide - Protein Information**

Name AMFR {ECO:0000303|PubMed:10456327, ECO:0000312|HGNC:HGNC:463}

**Function**E3 ubiquitin-protein ligase that mediates the polyubiquitination of lysine and cysteine residues on target proteins, such as CD3D, CYP3A4, CFTR, INSIG1, SOAT2/ACAT2 and APOB for proteasomal degradation (PubMed:[10456327](http://www.uniprot.org/citations/10456327), PubMed:[11724934](http://www.uniprot.org/citations/11724934), PubMed:[12670940](http://www.uniprot.org/citations/12670940), PubMed:[19103148](http://www.uniprot.org/citations/19103148), PubMed:[24424410](http://www.uniprot.org/citations/24424410), PubMed:[28604676](http://www.uniprot.org/citations/28604676)). Component of a VCP/p97-AMFR/gp78 complex that participates in the final step of endoplasmic reticulum-associated degradation (ERAD) (PubMed:[10456327](http://www.uniprot.org/citations/10456327), PubMed:[10456327](http://www.uniprot.org/citations/10456327), PubMed:[10456327](http://www.uniprot.org/citations/10456327)).

href="http://www.uniprot.org/citations/11724934" target="\_blank">11724934</a>, PubMed:<a href="http://www.uniprot.org/citations/19103148" target="\_blank">19103148</a>, PubMed:<a href="http://www.uniprot.org/citations/24424410" target="\_blank">24424410</a>). The VCP/p97-AMFR/gp78 complex is involved in the sterol-accelerated ERAD degradation of HMGCR through binding to the HMGCR-INSIG1 complex at the ER membrane (PubMed:<a href="http://www.uniprot.org/citations/16168377" target="\_blank">16168377</a>, PubMed:<a href="http://www.uniprot.org/citations/22143767" target="\_blank">22143767</a>). In addition, interaction of AMFR with AUP1 facilitates interaction of AMFR with ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase RNF139, leading to sterol-induced HMGCR ubiquitination (PubMed:<a href="http://www.uniprot.org/citations/23223569" target="\_blank">23223569</a>). The ubiquitinated HMGCR is then released from the ER into the cytosol for subsequent destruction (PubMed:<a href="http://www.uniprot.org/citations/16168377" target="\_blank">16168377</a>, PubMed:<a href="http://www.uniprot.org/citations/22143767" target="\_blank">22143767</a>, PubMed:<a href="http://www.uniprot.org/citations/23223569" target="\_blank">23223569</a>). In addition to ubiquitination on lysine residues, catalyzes ubiquitination on cysteine residues: together with INSIG1, mediates polyubiquitination of SOAT2/ACAT2 at 'Cys-277', leading to its degradation when the lipid levels are low (PubMed:<a href="http://www.uniprot.org/citations/28604676" target="\_blank">28604676</a>). Catalyzes ubiquitination and subsequent degradation of INSIG1 when cells are depleted of sterols (PubMed:<a href="http://www.uniprot.org/citations/17043353" target="\_blank">17043353</a>). Mediates polyubiquitination of INSIG2 at 'Cys-215' in some tissues, leading to its degradation (PubMed:<a href="http://www.uniprot.org/citations/31953408" target="\_blank">31953408</a>). Also regulates ERAD through the ubiquitination of UBL4A a component of the BAG6/BAT3 complex (PubMed:<a href="http://www.uniprot.org/citations/21636303" target="\_blank">21636303</a>). Also acts as a scaffold protein to assemble a complex that couples ubiquitination, retranslocation and deglycosylation (PubMed:<a href="http://www.uniprot.org/citations/21636303" target="\_blank">21636303</a>). Mediates tumor invasion and metastasis as a receptor for the GPI/autocrine motility factor (PubMed:<a href="http://www.uniprot.org/citations/10456327" target="\_blank">10456327</a>). In association with LMBR1L and UBAC2, negatively regulates the canonical Wnt signaling pathway in the lymphocytes by promoting the ubiquitin-mediated degradation of CTNBNB1 and Wnt receptors FZD6 and LRP6 (PubMed:<a href="http://www.uniprot.org/citations/31073040" target="\_blank">31073040</a>). Regulates NF-kappa-B and MAPK signaling pathways by mediating 'Lys-27'-linked polyubiquitination of TAB3 and promoting subsequent TAK1/MAP3K7 activation (PubMed:<a href="http://www.uniprot.org/citations/36593296" target="\_blank">36593296</a>). Required for proper lipid homeostasis (PubMed:<a href="http://www.uniprot.org/citations/37119330" target="\_blank">37119330</a>).

#### Cellular Location

Endoplasmic reticulum membrane; Multi-pass membrane protein. Note=Palmitoylation promotes localization to the peripheral endoplasmic reticulum

#### Tissue Location

Widely expressed..

### AMFR Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### AMFR Antibody (C-term) Blocking Peptide - Images

### AMFR Antibody (C-term) Blocking Peptide - Background

Autocrine motility factor (AMF) is a protein secreted by tumor cells that stimulates tumor motility. The gene for AMFR encodes a 323-amino acid polypeptide that has a single transmembrane domain

and several putative glycosylation sites. The protein sequence has some homology to human tumor protein p53.

#### **AMFR Antibody (C-term) Blocking Peptide - References**

Huang, B., et al., Biochem. Biophys. Res. Commun. 212(3):727-742 (1995). Watanabe, H., et al., J. Biol. Chem. 266(20):13442-13448 (1991).